Lariam (Mefloquine Hydrochloride)

Mefloquine interferes with the parasite’s heme detoxification pathway and disrupts membrane function, leading to accumulation of toxic heme and parasite death. It targets the intra‑erythrocytic stage of Plasmodium.

The dosing regimen is determined by the prescribing clinician based on indication, patient weight, and regional resistance patterns. Typical prophylactic schedules start one to two weeks before exposure and continue for four weeks after leaving the endemic area, while therapeutic regimens are individualized.

Safety data in pregnancy and lactation are limited. The drug is generally avoided during pregnancy unless the benefit outweighs potential risk, and breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as atovaquone‑proguanil or doxycycline, mefloquine offers a weekly dosing schedule for prophylaxis, which can improve adherence, but it has a higher incidence of neuro‑psychiatric side effects. Choice depends on patient tolerance, resistance patterns and travel duration.

Lariam tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer.

Lariam is taken orally with a full glass of water, preferably with food to reduce gastrointestinal upset. For prophylaxis, tablets are usually taken once weekly; for treatment, the schedule is prescribed by a qualified healthcare provider.

The most serious adverse reactions include neuro‑psychiatric events such as depression, anxiety, psychosis, and severe allergic reactions like anaphylaxis. Cardiac arrhythmias and hepatic toxicity have also been reported; patients should seek immediate medical attention if these occur.

Lariam is contraindicated in individuals with a known hypersensitivity to mefloquine or other quinoline antimalarials, patients with a history of severe psychiatric disorders, and those with significant cardiac conduction abnormalities. It should also be avoided in pregnant women unless no safer alternative is available.